The past month has seen a general downturn in biotech stocks, a movement back toward a mean after an incredible year of gains. That’s the generalization, and it is true, and it was forecast by Agora’s Dave Gonigam in the last week of December. At the time, I argued that biotech shouldn’t be seen as a whole but as individual stocks, and I still think that’s a good thing to keep in mind.
↧